glp 1 effect on pregnancy GLP-1 receptor agonists are increasingly used before pregnancy, but safety data have been limited., This meta-analysis pooled data from nearly 37,000 pregnancies and found no increased risk of major GLP-1 Receptor Agonist Exposure During

Currently, FDA regulates compounded drugs as one-of-a-kind medications modified when a person needs a different form or dosage

Approval for Cardiovascular Risk Reduction Ongoing cardiovascular outcomes trials (CVOT) studies clearly demonstrated that three of the diabetes incretin medications (liraglutide, dulaglutide and semaglutide) and one of the weight loss versions of this class (Wegovy) also reduce cardiovascular disease risk

No driving to clinics

Along with the heterogeneity of the disease and the lack of reliable biomarkers, the problem for developing specific treatments for PD is its multiple pathophysiological mechanisms, many of which are common to the mechanisms of T2DM development, including brain insulin resistance, impaired energy and glucose metabolism, mitochondrial dysfunction, chronic systemic inflammation, neuroinflammation, impaired lysosome function, and oxidative stress [56, 57]

Take the first step toward a healthier, happier you

Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial